Treatment of muscle-invasive bladder cancer.
In the USA, the incidence of bladder cancer is three-times higher in men than in women and it is the fourth most common cancer in men after prostate, lung and colorectal cancer. Muscle-invasive urothelial urinary bladder cancer has a very high mortality rate. This is regardless of intensive therapeutic efforts such as radical surgery in combination with oncological treatment options. The development of treatments with better outcomes regarding disease-specific survival and treatment-inflicted morbidity is likely to occur over the next few years. The significance of meta-analyses on the effect of neoadjuvant chemotherapy, the development of sentinel node dissection and the impact of the introduction of robot-assisted surgery on the possibility of performing minimally invasive surgery in advanced bladder cancer patients is discussed.
Sherif
Amir
A
Karolinska University Hospital, Department of Urology, 171 76 Stockholm, Sweden. amir.sherif@swipnet.se
Jonsson
Martin N
MN
Wiklund
N Peter
NP
D000970:Antineoplastic Agents / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D019060:Minimally Invasive Surgical Procedures / Q000379:methods; D019042:Muscle Neoplasms / Q000453:epidemiology / Q000628:therapy*; D009361:Neoplasm Invasiveness / Q000517:prevention & control; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000453:epidemiology / Q000628:therapy*
D000970:Antineoplastic Agents